MedTrace Logo

Efficacy and Safety of Prophylactic Antibiotics in Preventing Ventilator-associated Pneumonia: A Randomized, Double Blind, Placebo-controlled Trial

NCT07203638 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-10-02

No results posted yet for this study

Summary

Evaluate efficacy and safety of prophylactic antibiotics in preventing early ventilator-associated pneumonia

Conditions

  • Ventilator-Associated Pneumonia (VAP)

Interventions

DRUG

Beta Lactam Antibiotics

Beta lactam cefipim infusion (20mg/kg -12h -2 days ) total volume 10 ml

DRUG

Salin

Patient will receive .9 % saline (10ml /12h/2days)

Sponsors & Collaborators

  • Esraa Salah Mohamed Abdallah Eladl

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-01
Primary Completion
2025-11-01
Completion
2025-11-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07203638 on ClinicalTrials.gov